NCT05010590ACTIVE_NOT_RECRUITINGanonymous

Anabolic Therapy in Postmenopausal Osteoporosis

Sponsor

Source record

Massachusetts General Hospital

Phase

Source record

PHASE4

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Romosozumab, Denosumab

Indication / condition

AI-normalized

Postmenopausal Osteoporosis

Intervention

Source record

Romosozumab, Denosumab

Related intelligence directories

Indication directory: Postmenopausal Osteoporosis Modality directory: monoclonal antibody Target directory: Romosozumab

Source & freshness

Source record

NCT ID

NCT05010590

Original source

ClinicalTrials.gov

Source last updated

Apr 15, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05010590

Title

Anabolic Therapy in Postmenopausal Osteoporosis

Sponsor

Massachusetts General Hospital

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE4

Condition raw

Postmenopausal Osteoporosis

Condition normalized

Postmenopausal Osteoporosis

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Romosozumab, Denosumab

Target normalized

Romosozumab, Denosumab

Interventions

Romosozumab, Denosumab

Public preview

Source record

In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Anabolic Therapy in Postmenopausal Osteoporosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT05010590

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE4

Sponsor

Massachusetts General Hospital

Executive brief

Investment-Ready Snapshot

In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 15, 2026

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05010590

Indication

Postmenopausal Osteoporosis

Modality

monoclonal antibody

Target

Romosozumab, Denosumab

Intervention

Romosozumab, Denosumab

Source record